Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men

Journal of Clinical Psychopharmacology

Volumn 17, Issue 6, 1997, Pages 451-459

  Martin, David E ^a,d   Zussman, Barry D ^b,c   Everitt, Daniel E ^a   Benincosa, Lisa J ^b,c   Etheredge, Rickey C ^a   Jorkasky, Diane K ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c The Frythe   (United Kingdom)

^d PharmaResearch Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYTERFENADINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FEXOFENADINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; STEADY STATE; VOMITING;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HEADACHE; HEART; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; TERFENADINE;

EID: 0031399764     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199712000-00003     Document Type: Article

References (28)

1. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18:220-39.
2. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung 1982;32:1185-90.
3. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
4. Coutant JE, Westmark PA, Nardella PA, Walter SM, Okerholm RA. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991;570:139-48.
5. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P450 3A(4)in N-dealkylation and C-hydroxylation. Drug Metab Dispos Biol Fate Chem 1993;21:403-9.
6. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269: 1513-8.
7. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
8. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
9. Honig PK, Wortham DC, Zamani K, Cantilena L. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994; 7:148-56.
10. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect of fluconazole on the steady state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1992;53:630-6.
11. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995;58:310-5.
12. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-7.
13. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-12.
14. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
15. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
16. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
17. Paxil package insert. Philadelphia: SmithKline Beecham Pharmaceuticals, 1996.
18. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
19. Swims MP. Potential terfenadine-fluoxetine interaction. Ann Pharmacother 1993;27:1404-5.
20. Marchiando RJ, Cook MD. Probable terfenadine-fluoxetine-associated cardiac toxicity. Ann Pharmacother 1995;29:937-8.
21. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 1996;16: 101-3.
22. Bazett HC. An analysis of the times relations of electrocardiograms. Heart 1920;7:353-70.
23. Lessard D, Menabo W, Desrochers J, Menard C. A high sensitivity HPLC/MS method for the determination of terfenadine in human plasma [abstract]. Pharm Res 1993;10[suppl]:S-51.
24. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15: 657-80.
25. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153: 311-20.
26. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part D. J Clin Psychopharmacol 1996;16:345-55.
27. Tucker GT. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992;30:550-3.
28. Seldane product information. Physicians' desk reference. Montvale, NJ: Medical Economics Company, 1995:1428-30.